Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through foxp3+CD4+CD25+ T cells in peripheral blood

Pancreas

Volumn 42, Issue 1, 2013, Pages 130-134

  Ikemoto, Tetsuya ^a   Shimada, Mitsuo ^a   Komatsu, Masato ^a   Yamada, Shinichiro ^a   Saito, Yu ^a   Mori, Hiroki ^a   Morine, Yuji ^a   Imura, Satoru ^a   Bando, Yoshimi ^b   Utsunomiya, Tohru ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

3 dioxygenase (IDO); Foxp3; indoleamine 2; intraductal papillary mucinous neoplasm (IPMN); regulatory T cell

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BLOOD; BLOOD SAMPLING; CANCER RECURRENCE; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STAINING;

ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, PANCREATIC DUCTAL; CELL SEPARATION; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84872079174     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182575e4a     Document Type: Article

References (21)

1. International Association of Panacreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6(1-2):17-32.
2. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(14):1095-9203.
3. Ikemoto T, Yasutomo K, Yasutomo K, et al. Clinical roles of increased populations of Foxp3+ CD4+ T cells in peripheral blood in advanced pancreatic cancer. Pancreas. 2006;33(4):386-390.
4. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281(5380): 1191-1193.
5. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147-1154.
6. Munn DH. Indoleamine 2, 3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol. 2006;18(2):220-225.
7. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295-307.
8. Wang HY,Wang RF. Regulatory T cells and cancer. Curr Opin Immunol. 2007;19(2):217-223.
9. Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother. 2005;54(12): 1153-1161.
10. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-1164.
11. Ikemoto T, Tashiro S, Yasutomo K, et al. Donor-specific tolerance induced by simultaneous allogenic islet transplantation with CD4+CD25+ T-cell into hepatic parenchyma in mice. J Med Invest. 2004;51:178-185.
12. Sucher R, Fischler K, Oberhuber R, et al. IDO and regulatory T cell support are critical for cytotoxic T lymphocyteYassociated Ag-4 IgYmediated long-term solid organ allograft survival. J Immunol. 2012;188(1):37-46.
13. Vavrincova-Yaghi D, Deelman LE, Goor H, et al. Gene therapy with adenovirus-delivered indoleamine 2, 3-dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat. J Gene Med. 2011;13(7-8):373-381.
14. Nobuyoshi H, Kaoru O, Tomoo K, et al. Prevalence of FOXP3+ regulatory t cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12(18):5423-5434.
15. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002;297(5588):1867-1870.
16. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage nonYsmall lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4772.
17. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
18. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9:4404-4408.
19. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
20. Zelenay S, Lopes-Carvalho T, Caramalho I, et al. Foxp3+CD25-CD4+ T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci U S A. 2005;102:4091-4096.
21. Calderon B, Suri A, Miller MJ, et al. Dendritic cells in islets of Langerhans constitutively present B cellYderived peptides bound to their class II MHC molecules. Proc Natl Acad Sci U S A. 2008;105(16): 6126.